Genomic and drug-drug interaction mechanisms of interindividual variability in drug disposition

药物处置个体差异的基因组和药物相互作用机制

基本信息

项目摘要

Project Summary/Abstract Large degree of interindividual variability in drug response frequently compromises drug safety and efficacy. The long-term goal of my research is a mechanistic and clinical understanding of this variability and then personalized drug therapy. My research, funded mainly by NIGMS, has focused on the changes in drug pharmacokinetics due to both 1) inherited differences in drug disposition and 2) unpredictable drug-drug interactions (DDIs). This work produced new and novel mechanisms of drug disposition and identified genetic and DDI factors responsible for interindividual variability in drug and/or active metabolite exposure and effects. Novel in vitro and clinical phenotyping tools, genomic biomarkers and LC/MS/MS methods were developed that significantly advanced the science of drug disposition and stimulated collaborative and worldwide research endeavors. Examples include revision of the FDA package insert for efavirenz, development of dosing guidelines and position papers on efavirenz and CYP2B6, and the use of efavirenz as in vitro and in vivo probe of CYP2B6 activity. Yet, incomplete understanding of the mechanisms for interindividual variability in drug disposition persists for many other clinically important drugs and continues to compromise the implementation of maximum drug efficacy with minimal toxicity. This knowledge gap is the focus of this MIRA application. 1) The combined effect of genetic variability in drug disposition and DDIs on drug exposure and effect has rarely been studied. Efavirenz (a CYP2B6 substrate and a critical drug for the treatment of HIV) induces hepatic CYP2B6 and inhibits hepatic CYP1A2 in CYP2B6 genotype-dependent fashion. We hypothesize that interplay of genetic variations and DDIs is a key driver of intersubject differences in drug disposition and effect. In healthy volunteers genotyped for CYP2B6 variants, the stereoselective disposition and effect (e.g., pupil diameter) of methadone (a CYP2B6 substrate) and the disposition and effect (systolic and diastolic blood pressures) of tizanidine (a sensitive CYP1A2 substrate) will be determined at baseline and after pretreatment with efavirenz (600 mg/day PO for 17 days). 2) UGTs are differentially expressed in extrahepatic tissues, but their role in in drug metabolism is incompletely understood. Building on our recent publication with dolutegravir (a UGT1A1 and UGT1A9 substrate), we will test the hypothesis that modulation of extrahepatic metabolism of UGT substrates contributes to the variability in exposure of UGT substrates. In-depth in vitro kinetic and inhibition studies will be performed in microsomes derived from UGT genotyped human hepatic, intestinal and kidney tissues. 3) Some clinically observed complex DDIs are unpredictable based on current knowledge. Capitalizing on our work with bupropion-CYP2D6 interaction, in vitro DDI studies are proposed to identify the mechanistic basis of clinically observed DDIs, focusing on circulating metabolites/stereoisomers and less well- understood metabolic pathways. Appropriate in silico approaches will complement our studies. The results will enhance our ability to personalize drug therapy.
项目总结/文摘

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Zeruesenay Desta其他文献

Zeruesenay Desta的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Zeruesenay Desta', 18)}}的其他基金

Genomic and drug-drug interaction mechanisms of interindividual variability in drug disposition
药物处置个体差异的基因组和药物相互作用机制
  • 批准号:
    10598140
  • 财政年份:
    2022
  • 资助金额:
    $ 39.63万
  • 项目类别:
CYP2B6 genetic variations and drug interactions
CYP2B6 遗传变异和药物相互作用
  • 批准号:
    8077814
  • 财政年份:
    2010
  • 资助金额:
    $ 39.63万
  • 项目类别:
CYP2B6 Genetic Variations and Drug Interactions
CYP2B6 遗传变异和药物相互作用
  • 批准号:
    8885843
  • 财政年份:
    2007
  • 资助金额:
    $ 39.63万
  • 项目类别:
CYP2B6 genetic variations and drug interactions
CYP2B6 遗传变异和药物相互作用
  • 批准号:
    8077245
  • 财政年份:
    2007
  • 资助金额:
    $ 39.63万
  • 项目类别:
CYP2B6 genetic variations and drug interactions
CYP2B6 遗传变异和药物相互作用
  • 批准号:
    7258579
  • 财政年份:
    2007
  • 资助金额:
    $ 39.63万
  • 项目类别:
CYP2B6 Genetic Variations and Drug Interactions
CYP2B6 遗传变异和药物相互作用
  • 批准号:
    8501530
  • 财政年份:
    2007
  • 资助金额:
    $ 39.63万
  • 项目类别:
CYP2B6 Genetic Variations and Drug Interactions
CYP2B6 遗传变异和药物相互作用
  • 批准号:
    8666765
  • 财政年份:
    2007
  • 资助金额:
    $ 39.63万
  • 项目类别:
NAPROXEN - 13 C BREATH TEST TO RAPIDLY IDENTIFY CYTOCHROME P450 (CYP) 2C9 ACTIVI
萘普生 - 13 C 呼吸测试可快速识别 CYTOCHROME P450 (CYP) 2C9 ACTIVI
  • 批准号:
    7717552
  • 财政年份:
    2007
  • 资助金额:
    $ 39.63万
  • 项目类别:
CYP2B6 genetic variations and drug interactions
CYP2B6 遗传变异和药物相互作用
  • 批准号:
    7627220
  • 财政年份:
    2007
  • 资助金额:
    $ 39.63万
  • 项目类别:
CYP2B6 genetic variations and drug interactions
CYP2B6 遗传变异和药物相互作用
  • 批准号:
    7439199
  • 财政年份:
    2007
  • 资助金额:
    $ 39.63万
  • 项目类别:

相似海外基金

Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
  • 批准号:
    10591918
  • 财政年份:
    2023
  • 资助金额:
    $ 39.63万
  • 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
  • 批准号:
    23K15383
  • 财政年份:
    2023
  • 资助金额:
    $ 39.63万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
  • 批准号:
    23H03556
  • 财政年份:
    2023
  • 资助金额:
    $ 39.63万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
  • 批准号:
    23K17212
  • 财政年份:
    2023
  • 资助金额:
    $ 39.63万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
  • 批准号:
    22H03519
  • 财政年份:
    2022
  • 资助金额:
    $ 39.63万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
  • 批准号:
    563657-2021
  • 财政年份:
    2022
  • 资助金额:
    $ 39.63万
  • 项目类别:
    Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
  • 批准号:
    10521849
  • 财政年份:
    2022
  • 资助金额:
    $ 39.63万
  • 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
  • 批准号:
    10671022
  • 财政年份:
    2022
  • 资助金额:
    $ 39.63万
  • 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
  • 批准号:
    10670918
  • 财政年份:
    2022
  • 资助金额:
    $ 39.63万
  • 项目类别:
Adverse Effects of Using Laser Diagnostics in High-Speed Compressible Flows
在高速可压缩流中使用激光诊断的不利影响
  • 批准号:
    RGPIN-2018-04753
  • 财政年份:
    2022
  • 资助金额:
    $ 39.63万
  • 项目类别:
    Discovery Grants Program - Individual
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了